AACR 2023 | B7-H3-CAR T cells for the treatment of pediatric adrenocortical carcinoma

Outcomes for pediatric patients with unresectable, metastatic, or relapsed adrenocortical carcinoma (ACC) are dismal, and CAR-T cell therapy is a promising approach to improve outcomes for patients with this disease. Rebecca Epperly, MD, St. Jude Children’s Research Hospital, Memphis, TN, provides an overview of an evaluation into B7-H3 expression in primary pediatric ACC samples and B7-H3-CAR T activity in pediatric patient-derived xenograft (PDX) models. B7-H3 expression in 44 pediatric adrenocortical tumors (ACTs) was assessed, demonstrating a range of B7-H3 positivity, including 55% with expression above the threshold for eligibility for an active B7-H3-CAR T clinical trial (NCT04897321). Strikingly, B7-H3-CAR T eradicated 100% of tumors in mice and mice survived long term compared to controls. In conclusion, B7-H3 is expressed in a majority of pediatric ACTs and B7-H3-CAR T have potent anti-ACC activity. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.